目的 在冠状动脉疾病(coronary artery disease，CAD)患者中检测多种炎性反应因子与心房颤动(atrial fibrillation，AF)的关系。方法 本研究横断面调查了2008-2011年入院的所有冠状动脉疾病患者670例，其中32例患者伴有AF。记录患者人口统计学资料，并测量所有研究对象的白介素-6(Interleukin-6，IL-6)、C反应蛋白(C-reactive protein，CRP)、肿瘤坏死因子-α(tumor necrosis factor-α，TNF-α)、单核细胞趋化蛋白-1(monocyte chemoattractant protein-1，MCP-1)和纤维蛋白原(fibrinogen，Fg)水平。结果 AF患者和非AF患者的人口统计学资料存在差异，年龄、男性比例、左房容积在AF组中较高(P＜0.05)。单因素分析中，IL-6是唯一与AF相关的炎性反应因子(IL-6在AF和非AF的CAD患者中中位水平分别为3.54 和 2.36 ng/L，P=0.001)。多因素分析同样显示只有IL-6与AF相关(OR 1.75，95% CI：1.32～2.14，P=0.024)。结论 在冠状动脉疾病人群中，AF与IL-6水平升高密切相关，而与其他炎性反应因子，包括CRP、TNF-α、MCP-1、Fg不相关。
Abstract
Objective Previous studies suggest that inflammation factors are elevated in patients with atrial fibrillation (AF). However, coronary artery disease (CAD), which is often present in the same populations, is related to the raising of iflammation markers， and may present as a confounder in these studies. We therefore examined the association between biomarkers of inflammation and AF in patients with known CAD.Methods We performed a cross-sectional analysis of 670 patients with stable coronary artery diseases from July 2008 to June 2011, 32 of whom had AF. Interleukin-6 (IL-6), C-reactive protein (CRP), tumor necrosis factor-α(TNF-α)， monocyte chemoattractant protein-1 (MCP-1), and fibrinogen (Fg) levels were determined in all the patients. Results In the CAD patients with or without AF, demographic characteristics were different. Age, rate of male, smoking status, history of heart failure, and left atrial volume were higher in patients with AF. In unadjusted analyses, IL-6 was the only biomarker significantly associated with AF (median IL-6 3.54 and 2.36 ng/L in those with and without AF, respectively, P=0.001). Based on multivariate analysis, IL-6 was also the only factor related to AF (Odds Ratio 1.7, 95% CI: 1.32-2.14, P=0.024). Conclusions In patients with CAD， AF is significantly associated with elevated IL-6 levels. No associations were found with other biomarkers, including C-reactive protein, tumor necrosis factor-α, monocyte chemoattractant protein-1, and fibrinogen levels.
关键词
心房颤动 /
炎性反应因子 /
冠状动脉疾病 /
白介素-6
Key words
Atrial fibrillation /
Inflammation marker /
Coronary artery disease /
Interleukin-6
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］ Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin Ⅱ type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation［J］. J Am Coll Cardiol, 2003, 41:2197-2204.
［2］ Marcus G M, Yang Y, Varosy P D, et al. Regional left atrial voltage in patients with atrial fibrillation［J］. Heart Rhythm, 2007, 4:138-144.
［3］ Emerging Risk Factors Collaboration. C-reactive protein, fibrinogen, and cardiovascular disease prediction［J］. N Engl J Med, 2012,367(14):1310-1320.
［4］ Chugh S S, Blackshear J L, Shen W K, et al. Epidemiology and natural history of atrial fibrillation: clinical implications［J］. J Am Coll Cardiol, 2001, 37:371-378.
［5］ Guize L, Thomas F, Bean K, et al. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up［J］. Bull Acad Natl Med, 2007,191(4-5):791-805.
［6］ Chimenti C, Russo M A, Carpi A, et al. Histological substrate of human atrial fibrillation［J］. Biomed Pharmacother, 2010,64(3):177-183.
［7］ Chung M K, Martin D O, Sprecher D, et al. C-Reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation［J］. Circulation, 2001,104: 2886-2891.
［8］ Ellinor P T, Low A, Patton K K, et al. C-Reactive protein in lone atrial fibrillation［J］. Am J Cardiol, 2006, 97:1346-1350.
［9］ Goser S, Ottl R, Brodner A, et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy［J］. Circulation, 2005, 112:3400-3407.
［10］ Satoh M, Ishikawa Y, Itoh T, et al. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction［J］. Eur J Clin Invest, 2008,38(2):97-105.
［11］ Conway D S, Buggins P, Hughes E, et al. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation［J］. Am J Cardiol, 2004, 93:1368-1373, A1366.
［12］ Watson T, Arya A, Sulke N, et al. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in paroxysmal atrial fibrillation［J］. Chest, 2010, 137(4):869-876.
［13］ Goldberg Y H. Relationship between atrial fibrillation and left atrial size［J］. J Am Coll Cardiol, 2008, 51(7):776
［14］ Psychari S N, Apostolou T S, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation［J］. Am J Cardiol, 2005, 95:764-767.
［15］ Luckett L R, Gallucci R M. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice［J］. Br J Dermatol, 2007,156:1163-1171.
［16］ Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation［J］. Circulation, 2004, 109:363-368.
［17］ Gregory M, Marcus, Mary A W, et al. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: Data from the Heart and Soul Study［J］. Am Heart J, 2008, 2:303-309.
［18］ Roldán V, Marín F, Díaz J, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation［J］. J Thromb Haemost, 2012,10(8):1500-1507.
［19］ Hoshi T, Kitagawa K, Yamagami H, et al. Relations of serum highsensitivity C-reactive protein and interleukin-6 levels with silent brain infarction［J］. Stroke, 2005,36:768-772.
PDF(577 KB)
